STOCK TITAN

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Pluri Inc. unveils a groundbreaking method for expanding immune cells using proprietary technology, securing a new U.S. patent. The innovative 3D cell expansion technology mimics the natural lymph node environment, ensuring the integrity and functionality of immune cells. This advancement positions Pluri at the forefront of allogeneic cell therapy, promising significant therapeutic advancements and commercial success. The estimated total addressable market for immune cell engineering is projected to grow to $11.66 billion by 2030.
Positive
  • Pluri Inc. introduces a novel method for expanding immune cells with proprietary technology.
  • The 3D cell expansion technology replicates the natural lymph node environment for optimal cell expansion.
  • The patented technology positions Pluri at the forefront of allogeneic cell therapy innovation.
  • The estimated total addressable market for immune cell engineering is expected to reach $11.66 billion by 2030.
Negative
  • None.

The recent patent awarded to Pluri Inc. for a novel immune cell expansion technology is a significant development in the biotechnology sector. The patented system, which mimics the lymph node environment, is designed to optimize the expansion of immune cells while maintaining their therapeutic integrity. This advancement could streamline the production of cell-based therapies, which are critical in treating immune disorders and neurodegenerative diseases.

From a patent perspective, the exclusivity granted by this patent could provide Pluri with a competitive edge in the cell therapy market. It is essential to monitor how Pluri leverages this patent to secure partnerships, licensing deals, or to enhance their product pipeline. The proprietary nature of the technology could also serve as a barrier to entry for competitors, potentially leading to a stronger market position for Pluri.

Pluri's patented technology potentially addresses scalability issues present in current allogeneic cell therapies. The ability to expand immune cells on a mass scale efficiently may significantly reduce production costs and improve access to these therapies. Considering the total addressable market is estimated to reach $11.66 billion by 2030, Pluri's innovation could capture a substantial market share, especially if the technology proves to be adaptable across various immune cell types.

Investors should watch for Pluri's progress in clinical development and any strategic collaborations that may arise as a result of this technological edge. The projected CAGR of 22.5% indicates a rapidly growing market, with Pluri well-positioned to capitalize on this growth, provided the technology delivers on its promise and is adopted widely within the industry.

The financial implications of Pluri's new patent are multifaceted. The proprietary technology not only opens the door to new revenue streams through its potential impact on the cell therapy market but also enhances the company's valuation through intellectual property assets. Investors should consider the R&D expenses associated with further development and the time frame for commercialization when evaluating Pluri's financial health and future prospects.

Moreover, the market's response to this announcement could influence Pluri's stock performance in the short term. Long-term value, however, will hinge on the company's ability to convert this patented technology into successful treatments that gain regulatory approval and market acceptance.

  • Pluri’s patent enables mass-scale production of immune cell therapies
  • New patented technology is applicable for the expansion of a variety of immune cells
  • Technology sets stage for potential immune cell therapy advancements and targets an estimated total addressable market of $11.66 billion by 2030

HAIFA, Israel, April 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today unveiled a novel method for expansion of immune cells using proprietary technology and announced it was granted a new U.S. patent titled, “System and Methods for Immune Cells Expansion and Activation in Large Scale.”

Pluri's novel technology represents a paradigm shift in immune cell expansion methodologies because, unlike traditional approaches, its method employs a fundamentally different concept. Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality. This innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases.

Reaching More Patients by Creating Allogeneic Cell Product Candidates

Pluri's patented technology marks an important milestone in the field of allogeneic cell therapy, positioning the Company at the forefront of innovation. By addressing the critical challenges faced by current allogeneic cell therapies, such as limited donor cell availability and scalability issues, Pluri’s technology can potentially open doors to vast opportunities for therapeutic advancement and commercial success. With a commitment to pushing the boundaries of possibility, Pluri is poised to lead the charge towards realizing the full potential of allogeneic cell therapy, ultimately transforming the lives of patients worldwide.

“We believe that our continued investment in technology, paired with two decades of expertise, enable us to develop the next generation of medical treatments,” said Yaky Yanay, CEO and President of Pluri. “Pluri’s patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies. By harnessing the power of our proprietary technology, we are not only advancing the possibilities of allogeneic cell therapy, we are also reaffirming our commitment to improving patient outcomes worldwide.”

Total addressable market

The patented technology addresses the global immune cell engineering market size which is expected to reach $11.66 billion by 2030, from $2.82 billion in 2023, at a CAGR of 22.5% during the forecast period.

About Pluri Inc.

Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, foodtech and agtech. The Company also offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential of its technology, that its technology can potentially open doors to vast opportunities for therapeutic advancement and commercial success, the belief that its continued investment in technology, paired with two decades of expertise, enable it to develop the next generation of medical treatments, that its patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies, and the expected growth in the allogeneic cell therapy market. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.

Media Contacts

Investors: investor.relations@pluri-biotech.com

Israel Media: Shachar Yental at shacharye@gitam.co.il

U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com


FAQ

What is the new U.S. patent titled?

The new U.S. patent is titled “System and Methods for Immune Cells Expansion and Activation in Large Scale”.

How does Pluri's 3D cell expansion technology differ from traditional approaches?

Pluri's 3D cell expansion technology mimics the natural lymph node environment for immune cells, ensuring integrity and functionality.

What market size is the patented technology addressing?

The patented technology addresses the global immune cell engineering market size, expected to reach $11.66 billion by 2030.

Who is the CEO and President of Pluri Inc.?

Yaky Yanay is the CEO and President of Pluri Inc.

What are the potential benefits of Pluri's technology in allogeneic cell therapy?

Pluri's technology addresses challenges like donor cell availability and scalability issues, opening doors to therapeutic advancements and commercial success.

Pluri Inc.

NASDAQ:PLUR

PLUR Rankings

PLUR Latest News

PLUR Stock Data

32.87M
3.16M
24.62%
10.7%
0.25%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
HAIFA

About PLUR

pluristem therapeutics inc. (nasdaqcm: psti, tase: psti/pltr) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3d) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. pluristem’s placental expanded (plx) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. these cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. the company’s proprietary, 3d expansion technology can be used to grow plx cells in mass quantities with batch-to-batch consistency at pluristem’s fda, ema and pmda-approved, state-of-the art manufacturing facility. pluristem’s first product candi